Celcuity Inc. (CELC)
NASDAQ: CELC · Real-Time Price · USD
122.46
-2.79 (-2.23%)
At close: Apr 17, 2026, 4:00 PM EDT
122.00
-0.46 (-0.38%)
After-hours: Apr 17, 2026, 7:06 PM EDT
Celcuity Employees
Celcuity had 155 employees as of December 31, 2025. The number of employees increased by 68 or 78.16% compared to the previous year.
Employees
155
Change (1Y)
68
Growth (1Y)
78.16%
Revenue / Employee
n/a
Profits / Employee
-$1,142,206
Market Cap
5.92B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 155 | 68 | 78.16% |
| Dec 31, 2024 | 87 | 32 | 58.18% |
| Dec 31, 2023 | 55 | 10 | 22.22% |
| Dec 31, 2022 | 45 | 6 | 15.38% |
| Dec 31, 2021 | 39 | 9 | 30.00% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Caris Life Sciences | 1,846 |
| PTC Therapeutics | 991 |
| Rhythm Pharmaceuticals | 414 |
| Mirum Pharmaceuticals | 372 |
| Scholar Rock Holding | 289 |
| Cogent Biosciences | 258 |
| Centessa Pharmaceuticals | 118 |
| Erasca | 103 |
CELC News
- 25 days ago - Celcuity Inc. Reports Release of Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 weeks ago - Celcuity Schedules Release of Fourth Quarter and Full Year 2025 Financial Results and Webcast/Conference Call - GlobeNewsWire
- 5 weeks ago - Celcuity Announces Publication of Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Study of Gedatolisib Regimens in HR+/HER2- Advanced Breast Cancer in Journal of Clinical Oncology - GlobeNewsWire
- 7 weeks ago - Celcuity To Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Celcuity Appoints Charles Romp to its Board of Directors - GlobeNewsWire
- 2 months ago - Celcuity to Present at Upcoming Guggenheim Emerging Outlook: Biotech Summit 2026 - GlobeNewsWire
- 3 months ago - These 20 stocks are strong choices for momentum investors - Market Watch
- 3 months ago - Celcuity Announces FDA Acceptance of New Drug Application for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer - GlobeNewsWire